Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewGNF 5837 is a potent pan-Trk inhibitor. Displays antiproliferative effects in cellular Ba/F3 assays (IC50 values are 7, 9 and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively). Exhibits selectivity for Trk receptors over a range of kinases, with some activity at PDGFR and c-Kit (IC50 values are 0.87 and 0.91 μM respectively). Orally bioavailable.
GNF 5837 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 535.49 |
Formula | C28H21F4N5O2 |
Storage | Store at +4°C |
Purity | ≥98% (HPLC) |
CAS Number | 1033769-28-6 |
PubChem ID | 59397065 |
InChI Key | YYDUWLSETXNJJT-MTJSOVHGSA-N |
Smiles | O=C2NC1=CC(NC4=C(C)C=CC(NC(NC5=C(F)C=CC(C(F)(F)F)=C5)=O)=C4)=CC=C1/C2=C/C3=CC=CN3 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 53.55 | 100 | |
ethanol | 5.35 | 10 |
The following data is based on the product molecular weight 535.49. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.87 mL | 9.34 mL | 18.67 mL |
5 mM | 0.37 mL | 1.87 mL | 3.73 mL |
10 mM | 0.19 mL | 0.93 mL | 1.87 mL |
50 mM | 0.04 mL | 0.19 mL | 0.37 mL |
References are publications that support the biological activity of the product.
Albaugh et al (2012) Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models. ACS Med.Chem.Lett. 3 140 PMID: 24900443
If you know of a relevant reference for GNF 5837, please let us know.
Keywords: GNF 5837, GNF 5837 supplier, GNF5837, Trk, receptors, TrkA, TrkB, TrkC, pan-Trk, inhibitors, inhibits, antiproliferative, Receptors, 4559, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for GNF 5837 include:
Hyung-Jun et al (2020) Neurotrophic interactions between neurons and astrocytes following AAV1-Rheb(S16H) transduction in the hippocampus in vivo. Br J Pharmacol 177 668-686 PMID: 31658360
Chao et al (2021) Kv1.1 channels regulate early postnatal neurogenesis in mouse hippocampus via the TrkB signaling pathway. Elife 10 PMID: 34018923
Tsai et al (2017) Brain-derived neurotrophic factor (BDNF) -TrKB signaling modulates cancer-endothelial cells interaction and affects the outcomes of triple negative breast cancer. PLoS One 12 e0178173 PMID: 28604807
Do you know of a great paper that uses GNF 5837 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review GNF 5837 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.